Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2018, not a filing identified as Spyre Therapeutics, Inc. Aeglea was a clinical-stage biotechnology company developing enzyme-based therapeutics for rare genetic diseases and cancer. Its lead candidate, pegzilarginase, was being evaluated in three clinical trials. The company had no approved products and no product revenue.
Key Financial Metrics
| Metric | Q1 2018 | Q1 2017 | Change |
|---|---|---|---|
| Grant revenue | $1.5 million | $1.0 million | Up 54% |
| Research and development expense | $6.9 million | $4.9 million | Up 39% |
| General and administrative expense | $2.9 million | $2.4 million | Up 22% |
| Total operating expenses | $9.8 million | $7.3 million | Up 33% |
| Loss from operations | $(8.2) million | $(6.3) million | Loss increased 30% |
| Net loss | $(8.1) million | $(6.2) million | Loss increased 30% |
| Basic and diluted loss per share | $(0.49) | $(0.47) | Worsened |
| Net cash used in operating activities | $(7.4) million | $(5.4) million | Use increased |
As of March 31, 2018, cash and cash equivalents were $10.8 million, marketable securities were $32.7 million, and total cash, cash equivalents and marketable securities were $43.5 million. Working capital was $43.1 million. Total liabilities were $5.9 million, and the company reported no debt or credit facility. The accumulated deficit was $80.6 million.
Operating margins were not meaningful because the company had no product revenue and relied on grant revenue. Grant revenue represented approximately 15% of operating expenses, and the operating loss margin relative to grant revenue was substantially negative.
Material Changes Versus the Prior Comparable Period
- Grant revenue increased by $0.5 million, primarily because of higher qualifying research and development costs related to cancer clinical trials.
- Research and development expense increased by $1.9 million, driven by higher personnel costs and clinical development spending, partially offset by lower manufacturing costs.
- General and administrative expense increased by $0.5 million due primarily to additional headcount and compensation.
- Net loss increased by $1.9 million, or 30%, to $8.1 million.
- Operating cash burn increased by $2.0 million to $7.4 million.
- Cash and marketable securities declined from $50.3 million at December 31, 2017 to $43.5 million at March 31, 2018, while liabilities increased modestly from $5.7 million to $5.9 million.
- Investing activities provided $4.7 million in Q1 2018, primarily from marketable-security maturities, compared with $25.6 million used in Q1 2017, largely reflecting purchases of marketable securities.
Guidance, Outlook, Risks, and Unusual Items
- In April 2018, the company sold 5,046,510 common shares at $8.00 per share for gross proceeds of $40.4 million and net proceeds of approximately $37.7 million. Management stated that available resources, including this offering, were expected to fund operations through the middle of 2020, subject to assumptions that could prove incorrect.
- The CPRIT research grant covered the period through May 31, 2018. Approximately $5.7 million remained available for future collection, and grant receivables were $3.4 million at March 31, 2018.
- Management expected continued operating losses and increasing research and development spending as clinical trials and pipeline development progressed. Product revenue was not expected for several years, if ever.
- Management reported initial treatment effects in two Arginase 1 Deficiency patients and expected additional data in the third quarter of 2018. These early observations were based on a small number of patients and were not proof of efficacy.
- The company initiated or expanded clinical work in advanced solid tumors and began a Phase 1 combination study with Merck’s pembrolizumab in small cell lung cancer. It expected to initiate Phase 2 in the third quarter of 2018 and report Phase 1 topline safety and clinical activity in the fourth quarter of 2018.
- Material risks included clinical-trial failure or delay, adverse events, patient enrollment limitations, regulatory uncertainty, reliance on third-party manufacturers and contract research organizations, need for additional capital, intellectual-property challenges, competition, reimbursement uncertainty, and potential dilution from future equity financings.
- The company disclosed serious adverse events in prior and ongoing studies, including events possibly or probably related to pegzilarginase and deaths in oncology studies. A pediatric patient withdrew from an Arginase 1 Deficiency trial in March 2018 for personal reasons.
- The company discontinued pegzilarginase development for acute myeloid leukemia and myelodysplastic syndrome in December 2017 due to a lack of evidence of clinical benefit.
- There were no material pending legal proceedings, no off-balance-sheet arrangements, and no material changes to contractual obligations reported during the quarter.
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2018.
Most Important Facts for an Investor to Verify
- Confirm the issuer identity: the supplied filing is for Aeglea BioTherapeutics, Inc., while the request identifies Spyre Therapeutics, Inc.
- Verify the April 2018 equity offering, including shares issued, $40.4 million gross proceeds, and approximately $37.7 million net proceeds.
- Assess cash runway assumptions against the company’s quarterly operating cash burn and expected increases in clinical spending.
- Review the CPRIT grant’s remaining availability, reimbursement conditions, and expiration date of May 31, 2018.
- Evaluate the size, design, endpoints, safety data, and regulatory status of the pegzilarginase trials before assigning value to early clinical observations.
- Review potential dilution from the equity inducement plan, employee plans, the existing shelf registration, and the $20.0 million at-the-market facility.
- Examine third-party manufacturing, clinical-trial, licensing, and milestone obligations, including potential University of Texas milestone payments of up to $6.4 million.